Baxter International Inc.

Baxter International Inc.(BAX)の株式分析

$24.700

+0.193 (+0.78%)終値時点

Loading chart…
高値
24.830
始値
24.360
出来高加重平均価格
24.60
出来高
5.38M
時価総額
17.08B
安値
24.260
売買代金
132.22M
EV/EBITDA(TTM)
7.57

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

www.baxter.com

AI分析 of Baxter International Inc. (BAX)

買い

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.

バリュエーション指標

Baxter International Inc.(BAX)の現在の予想PERは11.57で、5年平均は13.82です。

予想PER

適正
5年平均 P/E
13.82
現在のP/E
11.57
割高
17.38
割安
10.26

予想EV/EBITDA

割安
5年平均 EV/EBITDA
11.74
現在のEV/EBITDA
7.57
割高
14.90
割安
8.59

予想PSR

適正
5年平均 P/S
1.48
現在のP/S
1.07
割高
2.02
割安
0.94

Alphio AI による BAX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BAX

$28.00

シナリオ価格

基

基本

基本 · 50%BAX

$25.49

シナリオ価格

弱

弱気

弱気 · 25%BAX

$18.18

シナリオ価格

BAX を保有するクジラ

R

RWC Partners Limited

+ を保有BAX

+6.79%

3か月リターン

イベントタイムライン

2026-10-20 (ET)

12:30:00

U.S. 10-Year Treasury Yield Falls to Near One-Month Lows

2026-08-19 (ET)

08:30:00

Baxter International Appoints John Rogers as CFO

2026-08-04 (ET)

09:00:00

Baxter International Launches Cash Tender Offers Up to $500M

2026-07-30 (ET)

09:00:00

Microsoft's Strong Earnings Boosts Stock Futures Rebound

ニュース

BAX のよくある質問 — Alphio AI が回答

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める